SLC5A2 and type 2 diabetes mellitus: However, an observational study using real-world data of more than 300,000 patients with T2DM, the majority of whom were without established CVD, also showed that the use of SGLT2 inhibitors resulted in a reduction in hospitalization for heart failure by 39% and all-cause mortality by 51% [42].